Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on January 20, 2023, spending HKD 1.243 million to repurchase 240,000 shares [1]

Group 1 - The company, Weigao Group (01066), announced a share buyback plan on January 20, 2026, involving an expenditure of HKD 1.2427 million to repurchase 240,800 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2026年1月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 事件 | 已發行股份（不包括庫存股 ...

Core Viewpoint - The sixth batch of national organized high-value medical consumables centralized procurement results have been announced, including 12 types of medical consumables, with execution expected around May 2026. The long-term growth potential of the high-value consumables sector is viewed positively due to the continuous increase in surgical and diagnostic volumes driven by aging populations and gradual import substitution [1]. Group 1: Event Details - On January 13, the results of the sixth batch of national organized high-value medical consumables centralized procurement were announced in Tianjin, involving 12 types of medical consumables, with 496 products from 227 companies bidding and 440 products from 202 companies winning [1]. - The procurement includes drug-coated balloons and urological intervention consumables, with a high selection ratio for the bidding products [2]. Group 2: Selection Process Optimization - The selection rules have been optimized to ensure that clinically recognized and capable products are chosen, stabilizing clinical usage [3]. - For differentiated products with certain functional innovations, a pricing coefficient based on clinical value has been established to reflect price differences reasonably [3]. - The lowest price is not the sole criterion for selection; if the lowest price is excessively low, a control benchmark of 65% of the average entry price is applied [3]. Group 3: Related Listed Companies - Companies related to coronary drug balloons include Lepu Medical, Blue Sail Medical, and MicroPort Medical [4]. - For peripheral drug balloons, companies such as Xianruida Medical-B, Gree创通桥, Xinmai Medical, and Lepu Medical are involved [4]. - In the urological intervention category, companies like Weili Medical and Weigao Group have all won bids, with examples of winning prices showing moderate reductions compared to earlier procurements [4].

Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company will repurchase 615,200 shares at a total cost of HKD 3.2072 million [1] - The buyback price ranges from HKD 5.18 to HKD 5.25 per share [1]

Core Viewpoint - Weigao Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company plans to repurchase 615,200 shares at a total cost of HKD 3.2072 million [1] - The buyback price ranges from HKD 5.18 to HKD 5.25 per share [1]

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on January 19, 2026, spending HKD 3.207 million to repurchase 615,000 shares at a price range of HKD 5.18 to HKD 5.25 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2026年1月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | ...

Core Viewpoint - The National Healthcare Security Administration reported on the bribery case involving a sales representative from a medical polymer products company, highlighting extensive bribery practices within a public hospital that compromised fair competition and increased medical costs [1][6][10]. Summary by Sections Bribery Details - The accused, Ci Mou Long, bribed staff at the Pu'er City People's Hospital with a total of RMB 3,950,000 in cash and 200 grams of gold bars, along with various medical supplies as kickbacks [1][6]. - From 2012 to 2020, Ci Mou Long made 11 payments totaling RMB 290,000 and USD 9,900 to the hospital's chief accountant for favorable payment processing [1][2]. - Over the years, multiple hospital staff members received kickbacks for various medical supplies, including RMB 1,191,243 in total from 2012 to 2018 [1][6]. Legal Consequences - Ci Mou Long was sentenced to 2 years and 6 months in prison and fined RMB 200,000 for bribery and corporate bribery [10]. - The case reflects ongoing issues in the medical supply industry, where improper incentives disrupt normal medical practices and inflate costs [6][10]. Industry Implications - The National Healthcare Security Administration is taking steps to regulate the procurement of medical supplies, aiming to reduce inflated prices and alleviate the financial burden on patients [10]. - The case underscores the need for stricter oversight and accountability in the medical supply sector to ensure fair competition and protect healthcare funds [6][10].

威高股份(01066)发布公告，于2026年1月16日，该公司斥资174.25万港元回购32万股。 ...